

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: JCA-13144

Serial No.: 10/578,943

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)


(37 CFR § 1.98(b))

Applicant: Soo-Hyun Kim *et al.*

Filing or 371(c) Date: 11/09/2006

Group Art Unit: 1647

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document / Patent Number	Publication / Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	6,277,969	08/21/2001	Le <i>et al.</i>	536	23.1	08/12/1998
	2	6,448,380	09/10/2002	Rathjen <i>et al.</i>	530	388.23	12/13/2000
	3	6,572,852	06/03/2003	Smith <i>et al.</i>	424	85.2	01/12/2001
	4	6,605,280	08/12/2003	Novick <i>et al.</i>	424	184.1	10/12/2000
	5	6,706,491	03/16/2004	Chang <i>et al.</i>	435	29	11/29/1999
	6	6,989,262	01/24/2006	Bejanin <i>et al.</i>	435	226	11/13/2001
	7	2003/0087270	05/08/2003	Schlegel <i>et al.</i>	435	6	06/12/2002
	8	2003/0092616	05/15/2003	Matsuda <i>et al.</i>	514	12	05/24/2002
	9	2003/0148316	08/07/2003	Lipford <i>et al.</i>	435	6	08/01/2002
	10	2003/0154032	08/14/2003	Pittman <i>et al.</i>	702	20	12/17/2001
	11	2005/0048490	03/03/2005	Azimzai <i>et al.</i>	435	6	09/26/2002
	12	2005/0130145	06/16/2005	Yue <i>et al.</i>	435	6	10/03/2002
	13	2005/0208496	09/22/2005	Ohtani <i>et al.</i>	435	6	07/31/2003
	14	2006/0088532	04/27/2006	Alitalo <i>et al.</i>	424	145.1	03/07/2003

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	15	WO 01/064886	09/07/2001	WIPO				
	16	WO 02/059260	08/01/2002	WIPO				
	17	WO 02/083898	10/24/2002	WIPO				
	18	WO 02/096943	12/05/2002	WIPO			X	
	19	WO 03/080640	10/02/2003	WIPO				
	20	WO 2005/016962	02/24/2005	WIPO				
	21	WO 2006/071088	07/06/2006	WIPO				
	22	EP 1487857	12/22/2004	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

	23	Banda <i>et al.</i> , "Mechanisms of effects of complement inhibition in murine collagen-induced arthritis," <i>Arthritis Rheum</i> , 46:3065, 2002
	24	Banda <i>et al.</i> , "Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein," <i>J Immunol</i> , 170:2100-2105, 2003
	25	Bendele <i>et al.</i> , "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis," <i>Arthritis Rheum</i> , 43:2648-2659, 2000
	26	Bernot <i>et al.</i> , "A transcriptional map of the FMF region" <i>Genomics</i> , 50:147-160, 1998
	27	Cohen, "Systemic Autoimmunity," in Paul (ed.) <i>Fundamental Immunology</i> , Lippincott-Raven Publishers: Philadelphia, pp. 1067-1088, 1999
	28	Dahl <i>et al.</i> , "Identification of a novel gene expressed in activated natural killer cells and T cells," <i>J Immunol</i> , 148:597-603, 1992
	29	Davis <i>et al.</i> , "Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update," <i>Ann Rheum Dis</i> , 59Suppl1:i41-3, 2000
	30	Faggioni <i>et al.</i> , "IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice," <i>J Immunol</i> , 167:5913-5920, 2001
	31	Firestein, "Rheumatoid Arthritis," in <i>Scientific American Medicine</i> , 2000

Examiner:

Date Considered:

EXAMINER:Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No. TCA-13144

Serial No.: 10/578,943

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

DISCLOSURE STATEMENT
(Use Several Sheets If Necessary)

Applicant: Soo-Hyun Kim *et al.*

Filing or 371(c) Date: 11/09/2006

Group Art Unit: 1647

(37 CFR § 1.98(b))

[illegible]

Examiner:

Date Considered:

EXAMINER:Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.